Mental or Behavioral Dysfunction
Transcend’s neuroplastogen posts positive mid-stage results in PTSD
TSND-201, Post-Traumatic Stress Disorder, Placebos, Statistical Significance, CAPS-5
GSK Launches Groundbreaking Study on Shingrix and Dementia Risk Reduction
GSK, Shingrix, dementia, UK Dementia Research Institute, Health Data Research UK, NHS data, real-world experiment
Novo Nordisk looks into starting GLP-1 drug trials for addiction
Glucagon-Like Peptide 1, Addictive Behavior
Australia steadfast on rejection of Eisai, Biogen’s Alzheimer’s therapy Leqembi
Lecanemab, Eisai, Leqembi, Alzheimer ‘s disease, Decision, Presenile dementia, Australia
Major Clinical Trial Failures of 2024: Setbacks in Neuroscience and Beyond
Clinical trials, drug development, neuroscience, ALS, Alzheimer’s disease, schizophrenia, Duchenne muscular dystrophy, oncology
Pfizer’s European Manufacturing Vulnerable to Potential US Tariffs, CEO Warns
Pfizer, Albert Bourla, European manufacturing, US tariffs, pharmaceutical industry, trade tensions, supply chain disruption
Newleos Therapeutics Launches with $93.5M to Advance Novel Neuropsychiatric Treatments
Newleos Therapeutics, mental health, neuropsychiatry, Roche assets, Series A funding, anxiety disorders, substance use disorders, GABA modulators
Newleos Therapeutics Launches with $93.5M to Develop Novel Neuropsychiatric Treatments
Newleos Therapeutics, Longwood Fund, neuropsychiatry, anxiety disorders, substance use disorders, Roche, GABA A -γ1, clinical trials
Semaglutide Shows Promise in Reducing Alcohol Consumption, Small Study Reveals
semaglutide, Ozempic, Wegovy, alcohol use disorder, GLP-1 drugs, alcohol cravings, weight loss medication, addiction treatment
Illumina’s Double-Edged Sword: Navigating US-China Trade Tensions
Illumina, China, tariffs, trade tensions, DNA sequencing, unreliable entity list, biotech industry, BIOSECURE Act